The Effect of Repeated Mass Drug Administration on the Transmission of Yaws: A Genomic Epidemiology Study

Amber Barton DPhil¹, Petra Pospíšilová PhD², Camila G Beiras PhD^{3,4}, Lucy N. John MD⁵, Wendy Houinei MPH⁵, Lorenzo Giacani PhD^{6,7}, David Šmajs PhD², Michael Marks PhD^{8,9,10}, Oriol Mitjà PhD^{3,4}, Mathew A Beale PhD^{1*}, Nicholas R Thomson PhD^{1,8*}

- Parasites and Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK
- 2. The Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 3. Fight Infectious Diseases Foundation, Hospital Universitari Germans Trías i Pujol, Badalona, Spain
- 4. Universitat Autònoma de Barcelona, Bellaterra, Spain
- 5. National Department of Health, Port Moresby, Papua New Guinea
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA
- 7. Department of Global Health, University of Washington, Seattle, WA, USA
- 8. Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
- 9. Hospital for Tropical Diseases, University College London Hospital, London, UK
- 10. Division of Infection and Immunity, University College London, UK

Abstract

1

2

3

4

5 6

7 8

9

10

11

12

13

14 15

16

17

18

19

20

2122

23

24

25

30

34

Background

- Yaws, a neglected tropical disease caused by *Treponema pallidum* subspecies *pertenue*, has evaded eradication, in part due to a high proportion of asymptomatic cases. A cluster-randomised trial in a yaws
- endemic area compared repeated mass drug administration (MDA) with one round of MDA followed
- by targeted treatment. Repeated rounds of MDA reduced active and latent prevalence of yaws but led
- 28 to emergence and spread of azithromycin resistance to three children. Here we aimed to finely delineate
- 29 the dynamics of *T. pertenue* sub-lineages over the course of this trial.

Methods

- 31 We performed whole genome sequencing directly on DNA from 263 swabs collected during this trial,
- 32 recovering 222 good-quality *T. pertenue* genomes. We examined the phylogenetic relationships
- between genomes linked to geospatial and patient metadata.

Findings

- We identified 29 fine-scale sub-lineages of *T. pertenue*, of which ten were eliminated by MDA, whilst
- 36 13 persisted in the control arm, one in the experimental arm, two in both study arms, and three were
- 37 first observed after commencing MDA. The two persistent sub-lineages had non-synonymous mutations
- 38 in penicillin binding proteins. One of these sub-lineages evolved macrolide resistance (N=3), and was
- associated with lowered treponemal antibody levels (p = 0.004) and longer ulcer duration (p = 0.015).
- Despite the study taking place within a relatively small geographic area (Namatanai District, in the
- 41 Island of New Ireland, Papua New Guinea) sub-lineages were geographically clustered, and older
- 42 children were more likely to share sub-lineages ($p = 6x10^{-9}$).

43 Interpretation

- Our findings show that the re-emergence of yaws after MDA was attributed to multiple sub-lineages.
- 45 The majority of these sub-lineages were detected in the population prior to MDA, and participants were
- 46 more likely to share sub-lineages within the same ward, suggesting that re-emergence was mostly driven
- 47 by local transmission. These findings could help inform future yaws elimination strategies.

48 Funding

- 49 European Research Council, European Union, Provincial Deputation of Barcelona, Barberà Solidaria
- 50 Regularisconcepted World Commisconcept that has not been certified by peer review and should not be used to guide clinical practice.

^{*}co-senior authors

Research in context

51 52 53

54

55

56 57

58

59

60

61

62 63

64

65

66 67

68

69

70

71

72

73

74

75

76

77

78

79

80

81 82

83

84 85

86

87

88

89

90 91

92

93 94

95

96

Evidence before this study

We searched PubMed on 24th July 2024 using the terms treponema * pertenue OR yaws, genom* OR sequencing, and "mass drug administration" OR azithromycin OR "mass treatment", without restrictions for language or date. Two studies were previously published on the current cohort from the Namatanai Province, Papua New Guinea, comparing three rounds of mass drug administration (MDA) with one round of MDA followed by targeted treatment. These studies used multi-locus sequencetyping and found that repeated MDA limited yaws to one sequence-type but resulted in three cases of macrolide resistance. A separate study used whole genome sequencing to find that after a single round of MDA on Lihir Island, Papua New Guinea, a rebound in yaws cases was caused by multiple sublineages of the same MLST, but evolution of macrolide resistance only occurred once. No studies have yet examined how repeated MDA affects the whole-genome diversity and evolution of yaws.

Added value of this study

Our findings show that re-emergence of yaws after MDA was caused by multiple sub-lineages, most of which were already present in the population before MDA. In the group undergoing three rounds of MDA there was still a small rebound in cases six months after the third round, caused by two "persistent" sub-lineages with mutations in penicillin-binding proteins. One of these sub-lineages was associated with lower treponemal antibody and developed macrolide resistance. Sub-lineages were more likely to be shared between older participants and those in close geographical proximity.

Implications of all the available evidence

These data suggest that re-emergence is predominantly driven by cases missed by the initial round of MDA rather than by importation of new cases. Much more efficient population suppression was achieved using three rounds of MDA, and this is likely due to more comprehensively treating the population and eliminating latent cases. Geographical clustering of sub-lineages suggests that elimination by maintaining cases at a low enough prevalence to result in stochastic "fade out" could be feasible and achieved by repeated mass drug administration. Transmission was found to be most common amongst older children, and targeted approaches focusing on these groups may be beneficial. However, ongoing surveillance for macrolide resistance will be needed to achieve eradication.

Introduction

The burden of the neglected tropical disease yaws, caused by infection with Treponema pallidum subspecies pertenue (T. pertenue)¹, is highest in Papua New Guinea and the Solomon Islands². Transmission is thought to be driven by skin-to-skin contact, with 75% of new cases in those aged below 15 years¹. While primary lesions heal in 3-6 months, disseminated secondary lesions affect skin and bones, and late-stage tertiary yaws can result in severe bone lesions¹. Without an eradication campaign, yaws would cause an estimated 1.6 million disability-adjusted life years from 2015-2050³.

A worldwide elimination campaign led by WHO and UNICEF between 1952-1964⁴ successfully reduced yaws 95% by treating clinically apparent cases with benzathine benzylpenicillin (BPG) injections. However, due to logistical barriers in using BPG in remote locations, combined with a high prevalence of asymptomatic latent cases, yaws has evaded eradication. In 2012 a randomised controlled trial established that single-dose oral azithromycin had a 96% efficacy in treating yaws⁵, raising the possibility of mass drug administration (MDA). This prompted WHO to launch the Morges Strategy for yaws eradication, providing MDA in endemic communities followed by targeted treatment of clinical cases at six-month intervals⁶.

In 2013-2016, a longitudinal study on Lihir Island, Papua New Guinea, found that the Morges strategy only reduced yaws cases temporarily, before a recrudescence driven by three distinct sub-lineages of multi-locus sequence-type (MLST) JG8/J_E11^{7,8}. Furthermore, five epidemiologically-linked cases with the A2059G 23S rRNA macrolide resistance mutation were detected. 36-61% of cases identified during targeted treatment rounds were due to residents missing the initial MDA, suggesting that multiple rounds may be necessary to disrupt transmission. To evaluate this strategy, a 2018-2019 clusterrandomised trial comprising 56,676 individuals was carried out in the Namatanai District of the Island of New Ireland, Papua New Guinea, comparing a control group following the Morges strategy (one round of MDA followed by two rounds of active case treatment every six months) with an experimental group undergoing three rounds of MDA⁹. After 18 months, active cases were reduced by three-fold in the control group, and 11-fold in the experimental group. However, three epidemiologically linked cases harbouring the 23S rRNA A2058G macrolide resistance mutation were identified at the final timepoint in the experimental group¹⁰.

Whilst MLST indicated that molecular diversity fell after MDA, 93% of cases belonged to a single sequence type⁹. We hypothesised that genome-scale resolution would allow us to define sub-lineages within the same MLST, allowing us to trace their distribution over the study. We therefore performed direct whole genome sequencing (WGS) on samples from the Namatanai trial and confirmed that MDA had a dramatic impact on T. pertenue diversity, and that further rounds of MDA prevented the rebound in diversity seen in the control group. We further used these genomic data to investigate the potential fitness advantages of two sub-lineages which persisted in both arms throughout the study.

Methods

97

98

99 100

101

102

103 104

105

106

107

108

109

110

111

112 113

114

115 116

117 118

119 120

121

122

123

124 125

126

127

128 129

130

131

132 133

134

135

136

137

138

139 140 141

Study population

Study samples were collected during a cluster-randomised trial where 38 wards in three local-level governments areas (LLGs) were randomised to either a control group following the Morges strategy or an experimental group undergoing three rounds of MDA (appendix 1 p2)9. Estimated population coverage ranged from 65% in the second treatment round to 99% in the follow-up survey. The trial protocol was approved by the Medical Research Advisory Committee of the Papua New Guinea National Department of Health. Informed oral consent was obtained from all trial participants, or for children, the parents/guardians of trial participants.

Whole genome sequencing and analysis

From 297 PCR-positive swabs, 263 unique samples underwent library preparation using the previously described pooled sequence-capture approach⁸ and whole genome sequencing (appendix 1 p2). Sequencing reads were prefiltered, trimmed and down-sampled then mapped to Samoa D T. pertenue reference genome (appendix 1 p2). We detected recombinogenic regions (appendix 1 p6), created a recombination-masked single nucleotide polymorphism (SNP) alignment including previously sequenced contextual samples, and inferred a maximum-likelihood phylogeny (appendix 1 pp2-3). Following ancestral reconstruction, samples were clustered into sub-lineages using rPinecone v0.1.0. with a SNP threshold of 1¹¹. ARIBA version 2.14.6¹² was used to infer MLST according to the scheme described by Medappa et. al¹⁰. Macrolide resistance alleles were inferred using the competitive mapping approach previously described⁸.

Pair-wise comparisons

For every possible pair of samples where participant metadata was available, excluding comparisons between the same sample, we identified whether pairs fell into the same sub-lineage, whether they were from the same age group or sex, or whether they were from the same LLG, ward, or neighbouring wards (appendix 1 p3). We then assessed whether pairs sharing the same sub-lineage were over-represented in each of these categories using a chi-squared test. We calculated Bonferroni-corrected p-values to account for multiple comparisons.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study.

Results

142

143

144

145

146 147

148 149

150

151

152 153

154

155

156

157

158

159

160

161

162

163

164

165

166 167

168

169 170

171 172

173

174 175

176

177

178 179

180

181

Namatanai T. pertenue genomes are genetically homogenous but can be subdivided into distinct sub-lineages

After sequencing and filtering the genomes for quality, our dataset comprised 222 novel T. pertenue genomes from Namatanai, and we contextualised these with 38 globally derived genomes, including 20 from nearby Lihir Island. Comparative analysis of genomes from Namatanai sequenced during this study indicated very close genomic relationships (Figure 1), with a median pair-wise SNP distance of 5 (range 0-139). Namatanai genomes fell within three phylogenetic clades corresponding to the MLST types J_E11 (n = 204), S_E22 (n = 11) and T_E13 (n = 7) described elsewhere^{9,10} and corresponding to types JG8, SE7 and TD6 described previously^{7,8}. Our use of whole genome sequencing enabled us to finely delineate these clades into 29 sub-lineages and 29 singletons with a distance of only 0-2 SNPs within each sub-lineage. For the purposes of this study, we adopted a sub-lineage naming system based on their properties within the trial ("PERS"- sub-lineage persisted in both arms throughout; "EXP"- sublineage found in the experimental group only; "ELIM"- sub-lineage eliminated from all trial groups; "ELIM Exp"- sub-lineage eliminated from the experimental arm only; "EMERG"- sub-lineage first detected after Round 1 MDA).

Our phylogenetic analysis using a globally derived genome collection indicated that genomes classified as ST J_E11 from Papua New Guinea and the Solomon Islands were phylogenetically distinct from all other *T. pertenue* genomes (Figure 1 showing all samples analysed; appendix 1 p7 with the predominant Papua New Guinea J_E11 clade collapsed). However, analysis within J_E11 showed that although genomes from the Solomon Islands were phylogenetically distinct, those from Lihir Island, Papua New Guinea⁸ co-occurred in the same sub-lineages as those in this study, suggesting the two islands share a T. pertenue population. Moreover, although all T. pertenue strains harbouring macrolide resistance SNPs were classified as J_E11 by MLST, the increased resolution afforded by WGS demonstrates that the sublineage that developed macrolide resistance through a 23S A2059G mutation in Lihir (sub-lineage ELIM Exp 03 in Figure 1) was phylogenetically distinct from the sub-lineage which developed resistance through the A2058G mutation in Namatanai (PERS 02).




Figure 1: Maximum likelihood whole genome sequencing phylogeny for samples collected in Namatanai and contextual genomes. A heatmap indicates the sample type, location from which samples were collected, MLST type, presence of macrolide-resistance conferring mutations 23S rRNA A2058G and A2059G, study arm, study round, and sub-lineage as determined by rPinecone.

T. pertenue genetic diversity was reduced after mass drug administration but rebounded within a year

We examined temporal patterns of T. pertenue genomic diversity, and observed a marked decline in Shannon's diversity index in both study arms following the first round of MDA (from 2.9 to 0 in the control arm, and from 2.8 to 1.1 in the experimental arm; appendix 1 p8). Despite targeted treatment of clinical yaws cases, diversity in the control arm rebounded to near pre-MDA levels (2.7) within 12-18 months, in contrast to the experimental arm, where diversity remained low (1.0). To further delineate these patterns, we examined temporal changes in frequency for the 29 sub-lineages comprising two or more samples. Of these, ten sub-lineages observed at baseline were eliminated entirely during the study. A total of sixteen sub-lineages were detected at baseline and persisted after MDA, in the control arm (thirteen sub-lineages), the experimental arm (one sub-lineage) or both arms (two sub-lineages) (Figure 2a). Three sub-lineages were not detected at baseline but were observed after MDA in the control arm.

Next, we investigated whether recrudescence in the experimental arm was driven by individuals missed during MDA, transmission from the control arm, or importation. At the end of the study, eight samples representing three sub-lineages were present in the experimental group, of which two (PERS_01 and PERS_02) had been detected in both arms throughout. The single PERS_01 sample left in the experimental arm was both spatially and temporally closer to PERS_01 samples from the control arm compared with the experimental arm (appendix 1 p9). Three of the four PERS_02 samples had associated location metadata, and all three were in wards where PERS_02 had previously been detected (appendix 1 p10). However, they were also less than 10km away from control wards containing

PERS_02 in the final round. Therefore, it was not possible to conclude whether PERS_02 persistence was driven by transmission from the control arm or within the experimental arm. EXP_01, which was only present in the experimental arm during the study, was detected in two wards in the final round, including the same ward it was originally detected in at baseline (appendix 1 p11). None of the sublineages present in the experimental arm in the final round had previously been found outside of the Namatanai District.

We next used pairwise comparisons to investigate geographical clustering of sub-lineages and found that pairs of samples from the same local-level government (LLG) were 1·3-fold more likely to share the same sub-lineage compared to pairs from different LLGs (Figure 2b). Likewise, pairs of samples from the same ward were 5.6-fold more likely to share the same sub-lineage compared to pairs from different LLGs, whilst pairs from neighbouring wards were 3.7-fold more likely. Notably in both the Namatanai and Sentral Niu Ailan LLGs, MDA had a dramatic effect on *T. pertenue* diversity, followed by a rebound in the control arm (appendix 1 p12). In contrast, *T. pertenue* diversity in the Matalai LLG was relatively low at the start of the study and remained relatively unaffected by MDA or targeted treatment, with the same two persistent sub-lineages dominating at the end of the study. This was still the case when the Namatanai and Sentral Niu Ailan LLG's sample size was adjusted to match that of Matalai LLG, suggesting this pattern is not wholly attributed to the smaller population of the Matalai LLG (appendix 1 p13).

Finally, we examined whether demographic factors were risk factors for transmission. Sex was not significantly associated with sharing sub-lineages (appendix 1 p14; p = 1, chi-squared test). Since the age of participants was unevenly distributed, we split participants into two equally sized groups, and those above the median age for this study (aged 9-56 years) were more likely to share the same sub-lineage with one another ($p = 6x10^{-9}$, chi-squared test) compared to samples from younger participants (aged 1-8 years).




Figure 2: a. Frequency of different sub-lineages each treatment round, stratified by study arm. Sub-lineages that were eliminated entirely by MDA are shown in pink; those that were only eliminated in the experimental arm in orange; those that emerged in 2019 in green; those that were persistent throughout the study in blue, and singletons in grey.

b. Proportion of pair-wise comparisons for which samples shared the same sub-lineage, stratified by sample location, study arm and age. Indicated p values are from a chi-squared test, Bonferroni-adjusted to account for each sample being compared to every other sample.

Two persistent sub-lineages are characterised by non-synonymous mutations in penicillinbinding proteins

As described earlier, two phylogenetically related sub-lineages (PERS_01 and PERS_02) persisted throughout interventions in both arms, suggesting they might possess a fitness advantage. We looked for phenotypic differences that may explain this and found that participants infected with PERS_02 reported a longer ulcer duration and had lower optical densities for a treponemal antibody assay compared with other sub-lineages (appendix 1 p19; Figure 3a). There was no significant difference in non-treponemal antibody (appendix 1 p15). We then tested whether any SNPs, including those highlighted as part of potential recombination blocks, were associated with these phenotypes. Across 222 samples from the Namatanai study, 88 SNPs were found in at least 5% of genomes (appendix 1 pp19-21). While none of these SNPs were associated with a longer ulcer duration, 55 SNPs in 44 genes were associated with decreased treponemal antibody (one-sided Mann-Whitney test, false discovery rate (fdr) after Benjamin-Hochberg multiple-testing correction < 0.05; Figure 3b). Amongst these 44

genes, proteins with signal peptides (15/44, 34%) were over-represented relative to the rest of the genome (142/1024, 14%) (p = 0.0008, Fisher's test).

260

261

262 263

264

265

266

267

268

269 270

271 272

273 274

275

276

277

278

279

280

281 282

283

284

285

286

Within the J_E11 MLST, 16 SNPs were present in at least 5% of genomes and occurred along the ancestral phylogenetic branches differentiating J_E11 sub-lineages from one another. Four of these SNPs were associated with decreased treponemal antibody (one-sided Mann-Whitney test, fdr < 0.05; Figures 3b and c), including a PERS 02-specific SNP causing a D744E mutation within the methyltransferase domain of cytoplasmic protein tp0288, which is involved with cell envelope biogenesis (appendix 1 p16). Tp0134, a paralogue of the adhesin tp0136¹³, varied at three sites within J_E11 (G61S, D74E and N76D), of which N76D was associated with lower treponemal antibody, and ¹³differed between PERS 02 and PERS 01. Using the fine-scale whole-genome phylogeny previously generated in Beale et al. 2021¹⁴ (appendix 1 p17) we found that in *Treponema pallidum* subspecies pallidum, the causative agent of syphilis, tp0134 varied at a site within the same loop (I78T) as T. pertenue.

Of the 16 SNPs which differentiated J_E11 sub-lineages, three were specific to the clade encompassing PERS 01 and PERS 02 (Figure 3d). This included two non-synonymous mutations in penicillin binding proteins: I415F in the transpeptidase domain of pbp2 (tp0760), and A506T in the transpeptidase domain of mrcA (tp0705) (appendix 1 p18). Both sub-lineages also possessed a A49V mutation in the cyclophilin-type peptidyl-prolyl cis-trans isomerase tp0947, an enzyme that catalyses an essential ratelimiting step in protein folding. We examined whether these SNPs were also present in T. pallidum (appendix 1 p17). I415F in pbp2 was present in seven T. pallidum SS14-lineage samples in China, while A506T mrcA was globally distributed, having arisen in multiple clades within the T. pallidum Nichols (71/96 samples) and SS14 (30/407 samples) lineages. The two Nichols clades with A506T mrcA were the only clades within the Nichols lineage to develop macrolide resistance. Another variant at this site, A506V, was present in the globally distributed SS14 lineage (23/407). However, it is not known whether these SNPs confer an observable phenotype.




Figure 3: a. Optical densities for a treponemal antibody assay and reported ulcer duration in days in participants infected with PERS 01, PERS 02 and other sub-lineages. P values for a Mann-Whitney test comparing PERS 02 with each other group is indicated.

b. Association of SNPs with lowered treponemal antibody compared with their position in the genome. SNPs with a minor allele frequency > 5% were included. SNPs are coloured by whether they were significantly associated with lowered treponemal antibody (one-tailed Mann-Whitney test, false discovery rate < 0.05) and whether they varied within the J_E11 MLST. The size of each point reflects the frequency of the SNP.

c. SNPs associated with lowered treponemal antibody that varied within J_E11, and SNPs that were specific to the clade encompassing PERS 01 and PERS 02. For samples where no reads mapped to the SNP locus, the nucleotide is denoted as "N".

Discussion

288

289

290

291

292

293

294

295

296

297 298

299 300

301 302

303 304

305

306 307

308

309

310

311

312 313

314

315

316

317

318 319

320

321

322

323

324 325

326

327

328

329

330

331 332

333

334

Understanding sources of yaws transmission will be key for informing intervention strategies if WHO is to achieve the target of yaws eradication by 2030¹⁵. In this study we used whole-genome sequencing to elucidate the dynamics and transmission of yaws in the Namatanai district following two possible MDA strategies. We observed that a single round of MDA only temporarily suppressed yaws diversity, followed by recrudescence mostly driven by sub-lineages that had been previously detected in the study population. Notably, two sub-lineages persisted in both arms of the study, of which one was associated with lower treponemal antibody and went on to develop three cases of macrolide resistance.

Inferring transmission of T. pallidum is challenging due to its high level of genome conservation, estimated to diverge by only one SNP every 6-8 years¹⁴. While MLST provides a useful tool for discriminating highly divergent genetic groups of T. pallidum at a global level¹⁶, it cannot distinguish sub-lineages at sufficient resolution to elucidate dynamics at a regional level. Previous research showed that T. pertenue in Namatanai was dominated by the J_E11 ST, particularly following the first MDA round^{9,10}. Here, the increased resolution afforded by whole-genome sequencing allowed us to subdivide samples considered identical by MLST into smaller sub-lineages with a distance of only 0-2 SNPs within each sub-lineage. Notably, we used the core genome here, and resolving and appropriately modelling incorporation of hypervariable regions using long-read or deep sequencing 17,18 could enable further delineation of recent transmission. To maximise the value of our dataset we included genomes with up to 50% missing sites, reflecting the challenge of sequencing low-abundance pathogens. While it is possible that we missed SNPs at low quality sites that would further delineate sub-lineages, because our analysis accounts for missing sites along ancestral branches we do not expect this to substantially impact our conclusions.

We found that yaws diversity dropped after the first round of MDA, remaining low in the experimental arm following two further MDA rounds at six-month intervals, but rebounding over the same period in the control arm. Previously it was observed that after the first round of MDA, multiple T. pertenue MLST types were still present in the control arm, indicating that a single MDA does not represent a strong bottleneck¹⁰. Here we found that not only were multiple MLST groups present after MDA, but also multiple J_E11 sub-lineages, 12/15 of these sub-lineages had been detected in the district before MDA, indicating that recrudescence was likely driven by a substantial number of cases missed during the initial round of MDA using the approach advocated by the Morges strategy. It is not yet clear whether diversity in the experimental group would return to similarly high levels 18 months after MDA cessation. However, repeated MDA successfully suppressed the T. pertenue population, which

modelling suggests increases the likelihood of stochastic "fadeout", where prevalence is low enough that stochastic effects can result in spontaneous eradication¹⁹.

335

336

337 338

339

340 341

342

343

344

345

346 347

348

349

350 351

352

353

354

355

356

357

358 359

360

361

362

363

364

365 366

367 368

369

370

371

372

373 374

375

376

377

378 379

380

381

Defining closely related but distinct sub-lineages also allowed us to quantify sub-lineage sharing between regions and sub-groups. Given the relatively small study region (covering a distance of approximately 300km) and slow genetic substitution rate of T. pertenue, we might have expected to find strains fully mixed throughout the region. However we observed substantial geographic clustering, which may be attributed to restricted travel options in these remote rural regions. This highly localised transmission suggests that yaws elimination could be more attainable than anticipated, as targeted treatment could be intensified in regions with clusters of cases, and clustering increases the likelihood of stochastic fadeout¹⁹. Spatial heterogeneity within implementation units will need to be considered when predicting prevalence. Furthermore, we observed sub-lineage sharing between neighbouring wards, indicating that implementation units should encompass at-least sub-districts in spatial scale. We also found that children aged nine or older, were more likely to share sub-lineages, which may reflect transmission chains within primary schools.

Finally, we investigated factors contributing to the success of the two sub-lineages that not only persisted but expanded in both study arms following MDA. These sub-lineages were both common at the beginning of the study, and harboured I415F and A506T mutations in penicillin-binding proteins pbp2 and mrcA respectively. Analysing previous data, we found that the A506T mrcA variant also arose in both major syphilis lineages, while the I415F pbp2 variant was present in syphilis samples from China²⁰. To our knowledge this is the first time these variants have been reported in yaws. While it is possible these variants arose and expanded in both T. pallidum subspecies pallidum and pertenue due to random genetic drift, a more likely explanation is positive selection for these mutations. It is unclear whether they confer increased resistance to sub-therapeutic doses of penicillin, or some other fitness advantage, but if so, this may explain why these two sub-lineages were common at the beginning of the trial. A case-control study is currently underway to investigate whether these variants are associated with treatment failure in syphilis ²¹. Another possibility is that because these proteins are associated with cell envelope biogenesis, mutations could reduce growth rate in vivo. Not only could this extend the latency period, allowing *T. pertenue* to avoid targeted antibiotic treatment, but it could also enhance tolerance to antibiotics that interfere with growth²². Future confirmation of this association could inform decisions on whether to intensify treatment in regions where persistent sub-lineages are circulating.

Ultimately, only three cases in one of these two sub-lineages developed macrolide resistance over the course of the study (PERS 02). Those infected with this sub-lineage exhibited a longer ulcer duration and lower treponemal antibody levels. Proteins with signal peptides were over-represented amongst those with variants associated with reduced antibody, and PERS 02 possessed variants in membrane lipoprotein tp0134, a paralogue of the adhesin $tp0136^{13}$. As periplasmic proteins are thought to be T. pallidum's principal immunogens after killing by phagocytes²³, variation in these proteins could prevent recognition. PERS 02 also harboured a mutation in a cytoplasmic protein involved in cell envelope biogenesis, which could slow bacterial growth and prevent T. pallidum reaching the critical capacity to activate immunity²³. Previous studies have found that pathogens exhibit enhanced evolutionary rates within hosts compared to rates inferred at the population level^{24–26}, suggesting that prolonged infections may increase the likelihood of *de novo* mutations such as those causing macrolide resistance. Prolonged infections also increase the likelihood of exposure to sub-therapeutic doses of azithromycin, creating a selection pressure for resistance.

Our findings here and elsewhere indicate that repeated MDA is more effective in reducing yaws cases than the single round MDA advocated in the Morges strategy⁹. However, this must be balanced against increased cost of conducting additional rounds of MDA. We observed marked geographic clustering even within a small area, suggesting that yaws elimination through targeting stochastic fade-out could be achievable. Furthermore, increased strain sharing between older children suggests that future campaigns targeting schools could offer a cost-effective solution for interrupting transmission. While three rounds of MDA did not achieve total elimination, repeated MDA did prevent resurgence in the diversity of yaws, and a strategy of long-term recurrent MDA on all neighbouring wards could be effective in maintaining prevalence at a sufficiently low level to achieve elimination. However, the potential selection pressure that repeated azithromycin MDA imposes towards macrolide resistance, both on *T. pertenue* and the microbiota, represents a reason for caution. Surveillance for macrolide resistance and treatment failure will be necessary for eradication. It is likely that a multipronged strategy involving MDA, targeted penicillin treatment and preventative interventions will be necessary to finally achieve eradication.

Contributors

 AB and MAB carried out the data analysis. AB prepared the figures and wrote the original draft of the manuscript. LNJ and WH carried out the initial clinical study with support from CG-B and OM. PP and DS carried out laboratory work. AB, CG-B, MAB, NRT, OM, LG and MM interpreted the data. All authors reviewed and approved the final manuscript.

Data sharing

Raw whole-genome sequencing data is deposited in the European Nucleotide Archive. Accession numbers and further data included in this analysis are provided in appendix 2.

Declaration of interests

The authors have no conflicts of interest to declare.

Acknowledgements

- The cluster randomised trial was funded by Fundació "la Caixa", Diputació de Barcelona, and Fundació Barberà Solidària. AB, MAB and NRT were supported by Wellcome funding to the Sanger Institute (220540/Z/20/A), and OM by the European Research Council under Grant Agreement number 850450. The work was partially financed by funds from the National Institute of Virology and Bacteriology project [Programme EXCELES, ID Project No. LX22NPO5103] funded by the European Union Next Generation EU to DS.
- The authors acknowledge support from the Sequencing teams, and Olivier Seret and the Parasites and Microbes Informatics team at the Wellcome Sanger Institute. This research was funded in whole, or in part, by the Wellcome Trust (220540/Z/20/A). For the purpose of open access, the authors have applied a CC-BY public copyright licence to any author-accepted manuscript version arising from this submission.

References

1 Mitjà O, Asiedu K, Mabey D. Yaws. *The Lancet* 2013; **381**: 763–73.

428	2	World Health Organization.	Yaws (Endemic treponematoses)	itoses).

- https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/yaws-430 (endemic-treponematoses).
- 431 3 Fitzpatrick C, Asiedu K, Jannin J. Where the Road Ends, Yaws Begins? The Cost-432 effectiveness of Eradication versus More Roads. *PLoS Negl Trop Dis* 2014; **8**. 433 DOI:10.1371/journal.pntd.0003165.
- 434 4 Maurice J. WHO plans new yaws eradication campaign. Elsevier Ltd, 2012 DOI:10.1016/S0140-6736(12)60581-9.
- Mitjà O, Hays R, Ipai A, *et al.* Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: An openlabel, non-inferiority, randomised trial. *The Lancet* 2012; **379**: 342–7.
- World Health Organization. Summary report of a consultation on the eradication of yaws. 2012.
- Mitjà O, Godornes C, Houinei W, *et al.* Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. *The Lancet* 2018; **391**: 1599–607.
- 8 Beale MA, Noguera-Julian M, Godornes C, et al. Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigation. *Lancet Microbe* 2020; **1**: e263–71.
- John LN, Beiras CG, Houinei W, et al. Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication. *New England Journal of Medicine* 2022; **386**: 47– 56.
- 450 10 Medappa M, Pospíšilová P, Madruga MPM, *et al.* Low genetic diversity of Treponema 451 pallidum ssp. pertenue (TPE) isolated from patients' ulcers in Namatanai District of 452 Papua New Guinea: Local human population is infected by three TPE genotypes. *PLoS* 453 *Negl Trop Dis* 2024; **18**: e0011831.
- Wailan AM, Coll F, Heinz E, *et al.* rPinecone: Define sub-lineages of a clonal expansion via a phylogenetic tree. *Microb Genom* 2019; **5**: 1–9.
- Hunt M, Mather AE, Sánchez-Busó L, et al. ARIBA: Rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom* 2017; **3**: 1–11.
- Djokic V, Giacani L, Parveen N. Analysis of host cell binding specificity mediated by the tp0136 adhesin of the syphilis agent treponema pallidum subsp. Pallidum. *PLoS Negl Trop Dis* 2019; **13**. DOI:10.1371/journal.pntd.0007401.
- 461 14 Beale MA, Marks M, Cole MJ, *et al.* Global phylogeny of Treponema pallidum lineages 462 reveals recent expansion and spread of contemporary syphilis. *Nat Microbiol* 2021; **6**: 463 1549–60.
- World Health Organization. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. 2020.
- 466 16 Grillova L, Jolley K, Šmajs D, Picardeau M. A public database for the new MLST 467 scheme for Treponema pallidum subsp. Pallidum: Surveillance and epidemiology of 468 the causative agent of syphilis. *PeerJ* 2019; **2019**: 1–13.
- 469 17 Addetia A, Lin MJ, Phung Q, *et al.* Estimation of Full-Length TprK Diversity in Treponema pallidum subsp. pallidum. 2020. DOI:10.1128/mBio.
- Lieberman NAP, Avendaño CC, Mohamed Bakhash SAK, *et al.* Genomic Epidemiology of Treponema pallidum and Circulation of Strains With Diminished tprK Antigen
- Variation Capability in Seattle, 2021–2022. *Journal of Infectious Diseases* 2024; **229**:
- 474 866–75.

475	19	Mooring EQ, Marks M, Mitjà O, et al. Programmatic goals and spatial epidemiology
476		influence the merit of targeted versus of population-wide interventions for yaws
477		eradication. bioRxiv 2019. DOI:10.1101/640326.

- Sun J, Meng Z, Wu K, *et al.* Tracing the origin of Treponema pallidum in China using nextgeneration sequencing. *Oncotarget* 2016; **7**: 42904–18.
- 480 21 Mi HF, Shen X, Chen XQ, Zhang XL, Ke WJ, Xiao Y. Association between treatment 481 failure in patients with early syphilis and penicillin resistance-related gene mutations 482 of Treponema pallidum: Protocol for a multicentre nested case—control study. *Front* 483 *Med (Lausanne)* 2023; **10**. DOI:10.3389/fmed.2023.1131921.
- 484 22 Kaldalu N, Tenson T. Slow growth causes bacterial persistence. *Sci Signal* 2019; **12**. DOI:10.1126/scisignal.aay1167.
- Radolf JD, Deka RK, Anand A, Šmajs D, Norgard M V., Yang XF. Treponema pallidum, the syphilis spirochete: Making a living as a stealth pathogen. Nat Rev Microbiol. 2016; **14**: 744–59.
- Culyba MJ, van Tyne D. Bacterial evolution during human infection: Adapt and live or adapt and die. *PLoS Pathog* 2021; **17**: 1–19.
- Chaguza C, Hahn AM, Petrone ME, et al. Accelerated SARS-CoV-2 intrahost evolution
 leading to distinct genotypes during chronic infection. Cell Rep Med 2023; 4.
 DOI:10.1016/j.xcrm.2023.100943.
- 494 26 Eldholm V, Norheim G, von der Lippe B, *et al.* Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. *Genome* 496 *Biol* 2014; **15**: 490.

497 498